Predictive Biomarkers in Phase II/III Clinical Trials

• Biomarker Targeted Randomized Design

Targeted design randomizes only marker positive patients to treatment or control arm. Untargeted design does not measure marker and randomizes all who otherwise are eligible.

• Biomarker Stratified Randomized Design

Stratified design randomizes both marker positive and negative patients.